| Literature DB >> 24559940 |
Hironobu Yanagie1, Syushi Higashi2, Koji Seguchi2, Ichiro Ikushima3, Mituteru Fujihara4, Yasumasa Nonaka5, Kazuyuki Oyama6, Syoji Maruyama7, Ryo Hatae7, Minoru Suzuki8, Shin-ichiro Masunaga8, Tomoko Kinashi8, Yoshinori Sakurai8, Hiroki Tanaka8, Natsuko Kondo8, Masaru Narabayashi8, Tetsuya Kajiyama9, Akira Maruhashi8, Koji Ono8, Jun Nakajima10, Minoru Ono11, Hiroyuki Takahashi12, Masazumi Eriguchi7.
Abstract
A 63-year-old man with multiple HCC in his left liver lobe was enrolled as the first patient in a pilot study of boron neutron capture therapy (BNCT) involving the selective intra-arterial infusion of a (10)BSH-containing water-in-oil-in-water emulsion ((10)BSH-WOW). The size of the tumorous region remained stable during the 3 months after the BNCT. No adverse effects of the BNCT were observed. The present results show that (10)BSH-WOW can be used as novel intra-arterial boron carriers during BNCT for HCC.Entities:
Keywords: Boron neutron capture therapy; Hepatocellular carcinoma; Intra-arterial injection; Water-in-oil-in-water emulsion
Mesh:
Substances:
Year: 2014 PMID: 24559940 DOI: 10.1016/j.apradiso.2014.01.014
Source DB: PubMed Journal: Appl Radiat Isot ISSN: 0969-8043 Impact factor: 1.513